Conditional IL-12 Fusion Proteins for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cytokine therapies, such as those using IL-2, face challenges due to their short serum half-lives and systemic toxicity, limiting their effectiveness and clinical use, especially in cancer treatment.
Innovation Solution
Development of fusion proteins that are conditionally active variants of IL-12, featuring a full-length polypeptide with reduced IL-12-receptor activating activity, which includes a blocking moiety and a protease-cleavable linker. This design allows for targeted activation of IL-12 in specific environments, such as the tumor microenvironment, while extending the serum half-life and reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokine therapies (such as IL-2) are used to boost immunity and treat cancer, then therapeutic efficacy is improved, but systemic toxicity increases and serum half-life decreases
Solution Approach 1:
The cytokine molecule is divided into two functional parts: a payload molecule (IL-12) that provides therapeutic activity and a blocking polypeptide moiety that masks the cytokine from receptor binding. This segmentation allows the cytokine to be delivered to the target site without premature activation, reducing systemic toxicity while maintaining therapeutic efficacy.
Solution Approach 2:
A protease-cleavable linker serves as an intermediary between the blocking polypeptide and the payload molecule. This linker is designed to be stable in circulation but cleavable by specific proteases at the target site (e.g., tumor microenvironment), enabling conditional activation of the cytokine only where needed, thereby reducing systemic side effects.
2Reliability
If cytokine therapies are used to treat cancer, then antitumoral activity is improved, but serum half-life decreases limiting effectiveness
Solution Approach 1:
The protease-cleavable linker acts as a temporal intermediary, keeping the cytokine in an inactive, masked state during circulation to extend its effective half-life. Upon reaching the target site and encountering activating proteases, the linker is cleaved, releasing the active cytokine for localized therapeutic action.
Solution Approach 2:
The cytokine is pre-delivered to the target site in an inactive, masked form that is stable in circulation. The blocking polypeptide moiety protects the cytokine from degradation and premature activation during its journey through the bloodstream, effectively extending its functional half-life before activation occurs.
3Reliability
If blocking polypeptide moiety is added to extend serum half-life and reduce toxicity, then therapeutic index is improved, but device complexity increases
Solution Approach 1:
Multiple functional elements (blocking polypeptide, protease-cleavable linker, and payload molecule) are merged into a single fusion protein construct. This unified structure simplifies production and delivery compared to using separate components, while still providing the desired pharmacokinetic and pharmacodynamic properties.
Solution Approach 2:
The blocking polypeptide moiety serves multiple functions simultaneously: it masks the cytokine from receptor binding to reduce toxicity, extends serum half-life by protecting from degradation, and can be designed to target specific tissues or cells. This multi-functionality reduces the need for additional separate components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins achieve targeted delivery and activation of IL-12 at the tumor site, minimizing systemic side effects and enhancing therapeutic efficacy by maintaining a serum half-life comparable to naturally occurring IL-12.
Implementation Method 1
the full-length polypeptides can include a blocking polypeptide moiety that also provides additional advantageous properties... Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, IL-12
Data Source
AI summary
The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.